Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
Inventors
Santos, Carlos • CHEN, IUAN-BOR • MORAN, JOSUE
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10730901-B2
Publication Date
2020-08-04
Expiration Date
Abstract
The present invention concerns materials and methods for treating an ocular Demodex mite infestation of an eye of a human or animal subject, or for treating a condition of the eye or skin associated with ocular Demodex mite infestation, the method comprising topically administering a composition comprising one or more spinosyn compounds to the ocular surface (conjunctiva and/or cornea) or other anatomical structure of the eye, or to an area adjacent the eye.
Core Innovation
The described invention provides a method for treating an ocular Demodex mite infestation of an eye of a human or animal subject by topically administering a miticidally effective amount of a composition comprising one or more spinosyn compounds. The composition is administered to one or more anatomical sites selected from among an eyelid, eyelid margin, eyelash, eyelash follicles, eyebrow, eyebrow follicles, or corner of the eye, where the ocular Demodex mite infestation is present at the time of administration.
The spinosyn-compound composition covers spinosyn structural embodiments via Formula (I), including pharmaceutically acceptable salts and example ratios for spinosyn A and spinosyn D, including spinosad as spinosyn A/D. The spinosyn compound content is described as 0.1% to 10% (w/v), with the composition formulated for topical ocular and periocular/anatomical-site administration.
The compositions include formulation options for ocular administration and periocular/anatomical-site treatment, including solutions, suspensions, ointments, creams, emulsions, and gels, as well as cosmetic product forms such as mascara, eyeliner, and eye shadow. Packaged embodiments include an applicator, swab, cosmetic pad, wipe, kit, and container, and the document further describes pH buffering and ophthalmically acceptable pH.
The document also describes optional pre-treatment confirmation of Demodex presence by identifying Demodex mites in vivo or in a biological sample ex vivo, or by detecting a molecule associated with Demodex mite presence. The detected molecules include chitin and lipase, antigens, and nucleic acids such as Demodex 16S rDNA and Demodex 18S rDNA, with detection approaches including PCR, real-time PCR, ELISA, and immunochemical detection.
Claims Coverage
The provided independent claim set contains 1 independent method claim. The claims are centered on topical administration of a spinosyn-compound, with inventive features including specific eye and anatomical sites, miticidally effective dosing, spinosyn structural coverage, and optional confirmation of Demodex presence.
Topical treatment to specified ocular Demodex anatomical sites
A method for treating an ocular Demodex mite infestation of an eye of a human or animal subject by topically administering a miticidally effective amount of a composition comprising one or more spinosyn compounds to one or more anatomical sites of the eye selected from among an eyelid, eyelid margin, eyelash, eyelash follicles, eyebrow, eyebrow follicles, or corner of the eye, wherein the ocular Demodex mite infestation is present at the time the composition is topically administered.
Spinosyn concentration range in the composition
The method is carried out with a composition containing 0.1% to 10% (w/v) of one or more spinosyn compounds.
Defined spinosyn chemical structure by Formula (I)
The method is carried out using one or more spinosyn compounds whose chemical structure is defined by Formula (I) or a pharmaceutically acceptable salt thereof.
Pre-treatment confirmation of Demodex presence
The method further confirms the presence of Demodex mites before administering treatment by identifying the mites in vivo or in a biological sample ex vivo, or by detecting a molecule associated with the mites' presence.
The claim coverage emphasizes a topical, miticidally effective spinosyn-compound treatment targeted to ocular anatomical sites where infestation is present, together with defined spinosyn embodiments and an optional Demodex presence confirmation approach.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?